Literature DB >> 8157028

Growth hormone and 17 beta-oestradiol treatment of Turner girls--2-year results.

R W Naeraa1, J Nielsen, K W Kastrup.   

Abstract

Girls with Turner syndrome are mainly characterized by growth retardation and gonadal insufficiency. In order to evaluate the effect of growth hormone (GH) and/or low dose 17 beta-oestradiol (E2) on growth and pubertal development, 39 Turner girls with a chronological age (CA) of 7.6-18.1 years were divided into three groups depending on pretreatment bone age (BA). They were treated with either GH 0.1 IE/kg per day (n = 13, BA 7.1-10.2), peroral E2 0.01 mg/kg per day (n = 8, BA 8.5-12.7) or both (n = 18, BA 10.5-15.3). In the 2nd year the E2 group also received GH, while the E2 dose was reduced 30%. In the 1st year height velocity (HV) expressed as standard deviation scores (SDS) increased in all groups (mean): from -0.4 to 3.3 (P < 0.01) in the GH group, -0.5 to 2.7 (P < 0.01) in the E2 group, and -0.8 to 4.6 (P < 0.001) in the GH+E2 group. A possible synergistic effect from combination therapy was seen, as HV increase was higher in group 3 than groups 1 and 2 (P < 0.05). In the 2nd year HV was unchanged in groups 1 and 2, while a clear decrease was seen in the GH+E2 group (P < 0.001). In the 1st year BA progression in the E2 group was rapid (1.9 BA/CA year) and higher than in the other groups (P < 0.05). In the 2nd year progression slowed down--particularly in the E2 group (0.7 BA/CA year, P = 0.07).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157028     DOI: 10.1007/bf01959210

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  14 in total

1.  Effect of oxandrolone on growth and final height in Turner's syndrome.

Authors:  R W Naeraa; J Nielsen; I L Pedersen; K Sørensen
Journal:  Acta Paediatr Scand       Date:  1990 Aug-Sep

2.  Treatment of short normal children with growth hormone--a cautionary tale?

Authors:  J M Walker; S A Bond; L D Voss; P R Betts; S A Wootton; A A Jackson
Journal:  Lancet       Date:  1990-12-01       Impact factor: 79.321

Review 3.  Consensus development conference: prophylaxis and treatment of osteoporosis.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-10

4.  Oestrogen therapy in Turner's syndrome.

Authors:  K W Kastrup
Journal:  Acta Paediatr Scand Suppl       Date:  1988

5.  Turner syndrome: spontaneous growth in 150 cases and review of the literature.

Authors:  M B Ranke; H Pflüger; W Rosendahl; P Stubbe; H Enders; J R Bierich; F Majewski
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

6.  Toward optimal estrogen-replacement therapy.

Authors:  R L Rosenfield
Journal:  N Engl J Med       Date:  1983-11-03       Impact factor: 91.245

7.  Growth-promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner's syndrome.

Authors:  M Vanderschueren-Lodeweyckx; G Massa; M Maes; M Craen; G van Vliet; C Heinrichs; P Malvaux
Journal:  J Clin Endocrinol Metab       Date:  1990-01       Impact factor: 5.958

8.  Does growth hormone treatment of patients with Turner's syndrome cause an abnormal body shape?

Authors:  W J Gerver; N M Drayer; A van Es
Journal:  Acta Paediatr       Date:  1992-09       Impact factor: 2.299

9.  Standards for growth and final height in Turner's syndrome.

Authors:  R W Naeraa; J Nielsen
Journal:  Acta Paediatr Scand       Date:  1990-02

10.  Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome.

Authors:  R G Rosenfeld; R L Hintz; A J Johanson; B Sherman; J A Brasel; S Burstein; S Chernausek; P Compton; J Frane; R W Gotlin
Journal:  J Pediatr       Date:  1988-08       Impact factor: 4.406

View more
  6 in total

Review 1.  Long-term results of growth hormone therapy in Turner syndrome.

Authors:  J H Bramswig
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

2.  Association between ER-α polymorphisms and bone mineral density in patients with Turner syndrome subjected to estroprogestagen treatment--a pilot study.

Authors:  Elżbieta Sowińska-Przepiera; Elżbieta Andrysiak-Mamos; Kornel Chełstowski; Grażyna Adler; Zbigniew Friebe; Anhelli Syrenicz
Journal:  J Bone Miner Metab       Date:  2011-01-27       Impact factor: 2.626

Review 3.  Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with turner syndrome: a systematic review and meta-analysis.

Authors:  Dahima Cintron; Rene Rodriguez-Gutierrez; Valentina Serrano; Paula Latortue-Albino; Patricia J Erwin; Mohammad Hassan Murad
Journal:  Endocrine       Date:  2016-07-29       Impact factor: 3.633

4.  Growth hormone treatment in Turner syndrome.

Authors:  A Zvulunov
Journal:  Eur J Pediatr       Date:  1994-12       Impact factor: 3.183

5.  Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.

Authors:  A Nordenström; S F Ahmed; E van den Akker; J Blair; M Bonomi; C Brachet; L H A Broersen; H L Claahsen-van der Grinten; A B Dessens; A Gawlik; C H Gravholt; A Juul; C Krausz; T Raivio; A Smyth; P Touraine; D Vitali; O M Dekkers
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

6.  Adult heights of 258 girls with turner syndrome on low dose of growth hormone therapy in Japan.

Authors:  Keinosuke Fujita; Susumu Yokoya; Kenji Fujieda; Akira Shimatsu; Katsuhiko Tachibana; Hiroaki Tanaka; Takakuni Tanizawa; Akira Teramoto; Yoshikazu Nishi; Yukihiro Hasegawa; Kunihiko Hanew; Reiko Horikawa; Toshiro Nagai; Toshiaki Tanaka
Journal:  Clin Pediatr Endocrinol       Date:  2010-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.